← Back
Data updated: Jun 28, 2026
EXELTIS USA INC
Pharma Pharmaceuticals
EXELTIS USA INC is a pharmaceutical company with 4 FDA-approved products.
2003
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules
EXELTIS USA INC's Key Drugs
EXELTIS USA INC's core commercial portfolio centers on TYBLUME, SLYND — its most strategically important drugs approved in the last 15 years.
EXELTIS USA INC's Recent FDA Approvals
New NDA/BLA approvals for EXELTIS USA INC over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
EXELTIS USA INC's Therapeutic Areas
Disease areas where EXELTIS USA INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
EXELTIS USA INC Pipeline Snapshot
Active clinical trials for EXELTIS USA INC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TYBLUME leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling